Liu Xi-bo, Sun Ai-jing, Wang Cheng, Chen Li-rong
Department of Pathology, Shaoxing People's Hospital, Shaoxing University, China.
Zhonghua Bing Li Xue Za Zhi. 2010 Sep;39(9):591-4.
To study the effect of BRG1 and BRM, the catalytic subunits expressed by SWI/SNF, in benign and malignant prostatic tissues and to correlate the BRG1/BRM expression with the development and progression of prostatic cancer.
The expression levels of the BRG1 and BRM proteins in benign and malignant prostatic tissues were studied using semi-quantitative immunohisto-chemistry. The results correlated with various clinical and pathologic parameters.
The average immuno-reactive score for BRG1 expression in prostatic cancer tissues was significantly higher than that in benign prostatic tissues (57+/-9.8 and 19+/-4.1, respectively, P = 0.000 17). The difference was more obvious in the high-grade cancer. On the other hand, BRM expression exhibited a heterogeneous pattern. The average immuno-reactive score for BRM expression was lower in cancer tissues than in benign tissues (112+/-17 and 151+/-19, respectively, P = 0.0047). BRG1 and BRM demonstrated a reciprocal expression pattern in benign and malignant tissues. The average immuno-reactive score for BRG1 expression was higher in the cancer cases with a larger tumor volume than in the cases with a smaller tumor volume (P = 0.0112).
The expression of BRG1 and BRM correlates with the development of prostatic cancer. Increased BRG1 expression may have certain implications in tumor progression.
研究SWI/SNF表达的催化亚基BRG1和BRM在前列腺良恶性组织中的作用，并将BRG1/BRM表达与前列腺癌的发生发展相关联。
采用半定量免疫组织化学法研究BRG1和BRM蛋白在前列腺良恶性组织中的表达水平。结果与各种临床和病理参数相关。
前列腺癌组织中BRG1表达的平均免疫反应评分显著高于良性前列腺组织（分别为57±9.8和19±4.1，P = 0.000 17）。在高级别癌症中差异更明显。另一方面，BRM表达呈现异质性模式。癌组织中BRM表达的平均免疫反应评分低于良性组织（分别为112±17和151±19，P = 0.0047）。BRG1和BRM在良性和恶性组织中呈现相互表达模式。肿瘤体积较大的癌症病例中BRG1表达的平均免疫反应评分高于肿瘤体积较小的病例（P = 0.0112）。
BRG1和BRM的表达与前列腺癌的发生相关。BRG1表达增加可能对肿瘤进展有一定影响。
